192 related articles for article (PubMed ID: 21041380)
1. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.
Tuccori M; Focosi D; Blandizzi C; Pelosini M; Montagnani S; Maggi F; Pistello M; Antonioli L; Fornai M; Pepe P; Rossi G; Petrini M
Oncologist; 2010; 15(11):1214-9. PubMed ID: 21041380
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment.
Sano Y; Nakano Y; Omoto M; Takao M; Ikeda E; Oga A; Nakamichi K; Saijo M; Maoka T; Sano H; Kawai M; Kanda T
Intern Med; 2015; 54(8):965-70. PubMed ID: 25876582
[TBL] [Abstract][Full Text] [Related]
3. [Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma].
Ota I; Katsura Y; Yoshida C; Yoshizawa K; Ohtani H; Sata T; Komeno T
Rinsho Ketsueki; 2010 Dec; 51(12):1786-8. PubMed ID: 21258190
[TBL] [Abstract][Full Text] [Related]
4. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
[TBL] [Abstract][Full Text] [Related]
5. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?
Hegele V; Stoll P; Wüst D; Ehrenbrink G; Grazziotin LR; Caregnato JP; Lindenmeyer LP
Int J Clin Pharm; 2013 Aug; 35(4):513-9. PubMed ID: 23737385
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.
Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD
Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
Yang JD; Girotra M; Vaid A; Duarte-Rojo A
J Ark Med Soc; 2013 Nov; 110(6):110-2. PubMed ID: 24367885
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.
Clifford DB; Ances B; Costello C; Rosen-Schmidt S; Andersson M; Parks D; Perry A; Yerra R; Schmidt R; Alvarez E; Tyler KL
Arch Neurol; 2011 Sep; 68(9):1156-64. PubMed ID: 21555606
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma.
Zhao W; Gao Y; Bai B; Cai QC; Wang XX; Cai QQ; Huang HQ
Expert Opin Drug Saf; 2015 Jan; 14(1):21-9. PubMed ID: 25412839
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
14. [Rapid-progressive decrease of cognitive and physical functions in a B-cell non-Hodgkin's lymphoma patient treated with rituximab/bendamustine].
Küllmer A; Herrmann G; Riecken B
Dtsch Med Wochenschr; 2013 Jun; 138(25-26):1355-9. PubMed ID: 23761057
[TBL] [Abstract][Full Text] [Related]
15. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.
Rashidi A; Oak E; Bartlett NL
Blood; 2015 May; 125(21):3354-5. PubMed ID: 25999445
[No Abstract] [Full Text] [Related]
16. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
17. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
[TBL] [Abstract][Full Text] [Related]
18. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
Molina A
Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
[TBL] [Abstract][Full Text] [Related]
19. New treatment approaches to indolent non-Hodgkin's lymphoma.
Seymour JF
Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]